Basis: Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBITDA ratio is N/A as of 2026-10-06T21:03:50.687Z.
Calculation as of: 2026-10-06T21:03:50.687Z.
Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: ca1169366ca7231828fa2f87c24c2e776dca628497ffd55dbb7a20e210c1aea1
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBITDA RATIO
N/A
Market Cap
$1.22B
EV/EBITDA Ratio
14.35x
TTM Avg
31.81x
3Y Avg
87.57x
5Y Avg
54.63x
Market Cap
$1.23B
EV/EBITDA Ratio
28.08x
TTM Avg
20.27x
3Y Avg
20.27x
5Y Avg
20.27x
Market Cap
$1.18B
EV/EBITDA Ratio
51.23x
TTM Avg
34.34x
3Y Avg
36.39x
5Y Avg
36.39x
Market Cap
$1.23B
EV/EBITDA Ratio
145.65x
TTM Avg
171.92x
3Y Avg
171.92x
5Y Avg
171.92x
| NAME | MARKET CAP | EV/EBITDA RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Tyra Biosciences, Inc. (TYRA) | $1.21B | N/A | N/A | N/A | N/A |
| Kardigan, Inc. (KARD)vs › | $1.21B | N/A | N/A | N/A | N/A |
| Damora Therapeutics, Inc. (DMRA)vs › | $1.20B | N/A | N/A | N/A | N/A |
| Innovage Holding Corp. (INNV)vs › | $1.22B | 14.35x | 31.81x | 87.57x | 54.63x |
| Cronos Group Inc. (CRON)vs › | $1.23B | 28.08x | 20.27x | 20.27x | 20.27x |
| MannKind Corporation (MNKD)vs › | $1.18B | 51.23x | 34.34x | 36.39x | 36.39x |
| Omada Health (OMDA)vs › | $1.23B | 145.65x | 171.92x | 171.92x | 171.92x |
| ORIC Pharmaceuticals, Inc. (ORIC)vs › | $1.24B | N/A | N/A | N/A | N/A |
| Nektar Therapeutics (NKTR)vs › | $1.14B | N/A | 9.05x | 9.05x | 14.70x |
| Amphastar Pharmaceuticals, Inc. (AMPH)vs › | $1.14B | 8.95x | 7.81x | 9.53x | 11.97x |
EV/EBITDA = Enterprise Value / EBITDA (TTM)
Enterprise value to EBITDA is a capital-structure-neutral valuation multiple, useful for comparing companies with different debt levels and tax rates.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
